{"transactions":[{"id":719792,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER DIRECTOR"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T15:01:44.000Z","date":"2026-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation (\"Hammi\") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":0.74,"expiration_date":"2032-09-14","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000912282-26-000902","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228226000902/form4.xml","form_type":"4"}},{"id":719791,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER DIRECTOR"}}],"security":"Stock Option (right to buy)","published_at":"2026-07-02T15:01:44.000Z","date":"2026-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation (\"Hammi\") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":0.66,"expiration_date":"2033-01-19","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000912282-26-000902","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228226000902/form4.xml","form_type":"4"}},{"id":719790,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER DIRECTOR"}}],"security":"Director Stock Option (Right to Buy)","published_at":"2026-07-02T15:01:44.000Z","date":"2026-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation (\"Hammi\") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Options vest 50% on first anniversary of grant date; remaining options vest 1/3 annually beginning on second anniversary of the grant date."}],"balance_after":0,"derivative":{"exercise_price":2,"expiration_date":"2034-02-05","underlying":"Common Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000912282-26-000902","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228226000902/form4.xml","form_type":"4"}},{"id":719789,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"FORMER DIRECTOR"}}],"security":"Common Shares","published_at":"2026-07-02T15:01:44.000Z","date":"2026-06-30","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17000,"price":1.72,"value":29240.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Disposed of pursuant to a board, shareholder and court-approved business arrangement agreement between the Issuer and Hammi Pharmaceuticals Co. Ltd., a South Korean Corporation (\"Hammi\") whereby a subsidiary of Hammi acquired all outstanding shares of the Issuer at a price of C$2.41 per share."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Converted from Canadian price of C$2.41 per share using an exchange rate of C$1.4 = US$1.00."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000912282-26-000902","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228226000902/form4.xml","form_type":"4"}},{"id":733129,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2026-06-17T23:02:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":12555,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":12555,"derivative":{"exercise_price":0.7293,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":12555},"source":{"system":"sec-edgar","filing":"0001104659-26-075278","document":"tm2618211-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075278/tm2618211-1_4seq1.xml","form_type":"4"}},{"id":733128,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-17T23:02:32.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":3135,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 16, 2026, and which will vest and be settled in common stock on June 16, 2027, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":48910,"source":{"system":"sec-edgar","filing":"0001104659-26-075278","document":"tm2618211-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465926075278/tm2618211-1_4seq1.xml","form_type":"4"}},{"id":752502,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option","published_at":"2026-06-03T20:30:21.000Z","date":"2026-06-01","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Capital Market on the date of grant, June 1, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests in three equal annual installments with the first tranche vesting on June 1, 2027, subject to the Reporting Person's continued service or employment, as applicable, on each such vesting date."}],"balance_after":30000,"derivative":{"exercise_price":1.06,"expiration_date":"2036-06-01","underlying":"Common Shares","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001493152-26-027081","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226027081/ownership.xml","form_type":"4"}},{"id":905633,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:23.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.8466,"value":33864.0,"ownership":{"direct":true},"balance_after":566991,"source":{"system":"sec-edgar","filing":"0001493152-26-006548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006548/ownership.xml","form_type":"4"}},{"id":905632,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-02-13T12:00:23.000Z","date":"2026-02-11","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":0.8265,"value":49590.0,"ownership":{"direct":true},"balance_after":526991,"source":{"system":"sec-edgar","filing":"0001493152-26-006548","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226006548/ownership.xml","form_type":"4"}},{"id":935677,"issuer":{"id":6721,"kind":"organization","name":"ONCOLYTICS BIOTECH INC"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Shares","published_at":"2026-01-20T21:30:18.000Z","date":"2026-01-16","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":1.0377,"value":103770.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0294 to $1.0499, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":466991,"source":{"system":"sec-edgar","filing":"0001493152-26-002879","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1129928/000149315226002879/ownership.xml","form_type":"4"}},{"id":1117241,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2025-06-09T20:07:40.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":1.81,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-25-057823","document":"tm2517366-8_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925057823/tm2517366-8_4seq1.xml","form_type":"4"}},{"id":1117240,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-09T20:07:40.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 5, 2025, and which will vest and be settled in common stock on June 5, 2026, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":45775,"source":{"system":"sec-edgar","filing":"0001104659-25-057823","document":"tm2517366-8_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465925057823/tm2517366-8_4seq1.xml","form_type":"4"}},{"id":1386432,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-15T12:31:44.000Z","date":"2024-10-11","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":2.68,"value":26800.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.70, inclusive. The reporting person undertakes to provide to the issuer or to the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein."}],"balance_after":44730,"source":{"system":"sec-edgar","filing":"0001104659-24-108377","document":"tm2426059-4_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924108377/tm2426059-4_4seq1.xml","form_type":"4"}},{"id":1471622,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2024-06-21T20:20:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":4185,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":4185,"derivative":{"exercise_price":4.07,"expiration_date":"2034-06-20","underlying":"Common Stock","underlying_shares":4185},"source":{"system":"sec-edgar","filing":"0001104659-24-073950","document":"tm2417666-6_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924073950/tm2417666-6_4seq1.xml","form_type":"4"}},{"id":1471621,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T20:20:11.000Z","date":"2024-06-20","kind":"grant","planned":false,"acquired":true,"shares":1045,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 20, 2024, and which will vest and be settled in common stock on June 20, 2025, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":34730,"source":{"system":"sec-edgar","filing":"0001104659-24-073950","document":"tm2417666-6_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924073950/tm2417666-6_4seq1.xml","form_type":"4"}},{"id":1576123,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche B Warrant","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The exercise price of the Tranche B Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $9.1125 per share or warrants for an exercise price of $9.1125 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The purchase price for the Tranche B Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Tranche B Warrants shall expire on March 13, 2029; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for APR-1051, and (ii) the daily VWAP of the Common Stock equals or exceeds $18.225 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1576122,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tranche A Warrant","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":3430,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price of the Tranche A Warrants is as follows: 3,430 shares of the Company's common stock at the exercise price of $7.29 per share or warrants for an exercise price of $7.29 minus $0.001 per share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The purchase price for the Tranche A Warrants is included in the purchase price for the shares of Common Stock reflected in Table I above."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Tranche A Warrants shall expire on March 13, 2027; provided, however, that (A) if (i) the Company publicly announces, the recommended Phase 2 dose for ATRN-119, and (ii) the daily VWAP of the Common Stock equals or exceeds $14.58 per share for any 30 consecutive Trading Day period commencing on or after the Trading Day on which the announcement was made, then the Termination Date shall be 30 days following the date on which both (i) and (ii) above have occurred."}],"balance_after":3430,"derivative":{"exercise_date":"2024-03-13","underlying":"Common Stock","underlying_shares":3430},"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1576121,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-03-15T00:53:36.000Z","date":"2024-03-13","kind":"purchase","planned":false,"acquired":true,"shares":6860,"price":7.29,"value":50009.4,"ownership":{"direct":true},"balance_after":33685,"source":{"system":"sec-edgar","filing":"0001104659-24-034672","document":"tm248935-3_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465924034672/tm248935-3_4seq1.xml","form_type":"4"}},{"id":1655909,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true}}],"security":"Director Stock Option (Right to Buy)","published_at":"2024-02-07T21:56:08.000Z","date":"2024-02-05","kind":"grant","planned":false,"acquired":true,"shares":3333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest as follows:  50% on February 5, 2025; 25% on February 5, 2026; and 25% on February 5, 2027."}],"balance_after":3333,"derivative":{"exercise_price":2,"expiration_date":"2034-02-05","underlying":"Common Shares","underlying_shares":3333},"source":{"system":"sec-edgar","filing":"0000912282-24-000126","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228224000126/form4.xml","form_type":"4"}},{"id":1774203,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true}}],"security":"Common Shares","published_at":"2023-09-25T21:03:39.000Z","date":"2023-09-22","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":3.14,"value":53380.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.13 to $3.14, inclusive. The reporting person undertakes to provide to Aptose Biosciences Inc.., any security holder of Aptose Biosciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":17000,"source":{"system":"sec-edgar","filing":"0000912282-23-000385","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882361/000091228223000385/form4.xml","form_type":"4"}},{"id":1797350,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to Buy)","published_at":"2023-08-25T01:48:22.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":2000,"derivative":{"exercise_price":3.65,"expiration_date":"2033-08-23","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001104659-23-095016","document":"tm2324788-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923095016/tm2324788-1_4seq1.xml","form_type":"4"}},{"id":1797349,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-25T01:48:22.000Z","date":"2023-08-23","kind":"grant","planned":false,"acquired":true,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on August 23, 2023, and which will vest and be settled in common stock on August 23, 2024, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":26825,"source":{"system":"sec-edgar","filing":"0001104659-23-095016","document":"tm2324788-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923095016/tm2324788-1_4seq1.xml","form_type":"4"}},{"id":1861680,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-08T20:34:28.000Z","date":"2023-06-07","kind":"purchase","planned":false,"acquired":true,"shares":6029,"price":3.6809,"value":22192.1461,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.65 to $3.70, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects a one-for-20 reverse split, effective as of 5:00 p.m. Eastern Time on February 10, 2023."}],"balance_after":26325,"source":{"system":"sec-edgar","filing":"0001104659-23-069421","document":"tm2318158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923069421/tm2318158-1_4seq1.xml","form_type":"4"}},{"id":1861679,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-08T20:34:28.000Z","date":"2023-06-06","kind":"purchase","planned":false,"acquired":true,"shares":4068,"price":3.6294,"value":14764.3992,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.4984 to $3.75, inclusive. The reporting person undertakes to provide to Aprea Therapeutics, Inc., any security holder of Aprea Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth."}],"balance_after":20296,"source":{"system":"sec-edgar","filing":"0001104659-23-069421","document":"tm2318158-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465923069421/tm2318158-1_4seq1.xml","form_type":"4"}},{"id":2049024,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-24T01:03:26.000Z","date":"2023-01-19","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the options vest on January 19, 2024, twenty-five percent (25%) vest on January 19, 2025, and twenty-five percent (25%) vest on January 19, 2026."}],"balance_after":100000,"derivative":{"exercise_price":0.66,"expiration_date":"2033-01-19","underlying":"Common Shares","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001567619-23-001169","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882361/000156761923001169/doc1.xml","form_type":"4"}},{"id":2157914,"issuer":{"id":33387,"kind":"organization","name":"Aptose Biosciences Inc.","symbol":"APTO"},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-09-16T21:32:52.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Fifty percent (50%) of the options vest on September 14, 2023, twenty-five percent (25%) on September 14, 2024, and twenty-five percent (25%) on September 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Fifty percent (50%) of the options vest on September 14, 2023, twenty-five percent (25%) on September 14, 2024, and twenty-five percent (25%) on September 14, 2025."}],"balance_after":50000,"derivative":{"exercise_price":0.74,"expiration_date":"2032-09-14","underlying":"Common Shares","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001567619-22-017563","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/882361/000156761922017563/doc1.xml","form_type":"4"}},{"id":2198783,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2022-08-01T21:06:38.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":29575,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":29575,"derivative":{"exercise_price":1.09,"expiration_date":"2032-07-28","underlying":"Common Stock","underlying_shares":29575},"source":{"system":"sec-edgar","filing":"0001104659-22-084775","document":"tm2222147-10_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922084775/tm2222147-10_4seq1.xml","form_type":"4"}},{"id":2198782,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-08-01T21:06:38.000Z","date":"2022-07-28","kind":"grant","acquired":true,"shares":5995,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on July 28, 2022, and which will vest and be settled in common stock on July 28, 2023, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":324575,"source":{"system":"sec-edgar","filing":"0001104659-22-084775","document":"tm2222147-10_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922084775/tm2222147-10_4seq1.xml","form_type":"4"}},{"id":2263036,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-05-19T20:31:21.000Z","date":"2022-05-18","kind":"purchase","acquired":true,"shares":50000,"price":0.71,"value":35500.0,"ownership":{"direct":true},"balance_after":318580,"source":{"system":"sec-edgar","filing":"0001104659-22-062920","document":"tm2216022d2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000110465922062920/tm2216022d2_4seq1.xml","form_type":"4"}},{"id":2647059,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-01T23:00:56.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":22750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests in full on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":22750,"derivative":{"exercise_price":4.88,"expiration_date":"2031-06-30","underlying":"Common Stock","underlying_shares":22750},"source":{"system":"sec-edgar","filing":"0001567619-21-012872","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000156761921012872/doc1.xml","form_type":"4"}},{"id":2647058,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-07-01T23:00:56.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":4610,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units which were granted on June 30, 2021, and which will vest and be settled in common stock on June 30, 2022, subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":268580,"source":{"system":"sec-edgar","filing":"0001567619-21-012872","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000156761921012872/doc1.xml","form_type":"4"}},{"id":3094809,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true}}],"security":"Stock Option (right to Buy)","published_at":"2020-07-01T22:06:49.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":5600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on June 30, 2021 subject to the reporting person's continued service on the Issuer's board of directors through and including the applicable vesting date and subject to acceleration under certain conditions."}],"balance_after":5600,"derivative":{"exercise_price":38.78,"expiration_date":"2030-06-30","underlying":"Common Stock","underlying_shares":5600},"source":{"system":"sec-edgar","filing":"0000905148-20-000751","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000090514820000751/form4.xml","form_type":"4"}},{"id":3396451,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2019-10-07T23:33:13.000Z","date":"2019-10-07","kind":"exercise","acquired":false,"shares":263970,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options vested in connection with the completion of the Issuer's initial public offering."}],"balance_after":0,"derivative":{"exercise_price":0.07,"expiration_date":"2025-09-04","underlying":"Common Stock","underlying_shares":263970},"source":{"system":"sec-edgar","filing":"0001140361-19-018086","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018086/form4.xml","form_type":"4"}},{"id":3396450,"issuer":{"id":7948,"kind":"organization","name":"Aprea Therapeutics, Inc."},"owners":[{"id":33388,"kind":"person","name":"Seizinger Bernd R.","position":1,"cik":"0001789042","reported_name":"Seizinger Bernd R.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-10-07T23:33:13.000Z","date":"2019-10-07","kind":"exercise","acquired":true,"shares":263970,"price":0.07,"value":18477.9,"ownership":{"direct":true},"balance_after":263970,"source":{"system":"sec-edgar","filing":"0001140361-19-018086","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1781983/000114036119018086/form4.xml","form_type":"4"}}]}